|Effective technology transfer is the alchemy that means that the groundbreaking research of Prof. Yoram Reiter will soon become the far-reaching vaccine, treatment or cure available for a range of diseases. The|
Technion flagship company AIT is just one example of the tremendous hope brought for human health by the effective process of technology transfer.
A world leader in recombinant antibodies and their applications in targeting diseased cells, Prof Yoram Reiter and his team of researchers and colleagues are becoming exciting global examples of how effective technology transfer, scientific brainpower and research can be put to work for the sake of all.
The flagship company, Applied Immune Technologies (once BioMimic Pharma) is developing new therapeutic molecules and diagnostic reagents for a wide range of cancer and viral diseases, based on a novel platform technology of generating T-Cell Receptor-Like (TCRL) human recombinant antibodies mimicking the natural immune surveillance system. What it means for us, is that antibodies can be engineered as cures or preventions to some of the most threatening diseases.
"We have 25 antibodies for different kinds of diseases," says Dr. Mira Peled-Kamar, "But right now, in partnership with Mankind, we are developing treatment for Melanoma in order to get "proof of concept". The applications of this method are huge.
Four graduate students from Prf. Reiter's lab now work at AIT. "They are great,| says Peled-Kamar, "They know so much of the technology. The project manager Galit Denkberg was the first student in Yoram's lab - dhr esd thr first to isolate the antibody - Yoram's idea...her hands."
Something for Every bad thing...
Prof Yoram Reiter's research opens the possibility of future cures and vaccines to almost any disease known to man.... or any yet to come. It is a case of effective technology transfer being a true gift for humanity...
More about AIT
Applied Immune Technologies (AIT) is a drug development company specializing in T-Cell Receptor-Like (TCRL) antibodies for therapeutic and diagnostic applications in a variety of cancer, viral and autoimmune diseases, as well as identification and validation of novel therapeutic targets.
From Target Discovery to Therapeutic Antibodies
AIT's core technology platforms encompass the identification and validation of novel MHC-based targets, as well as development of therapeutic Human Recombinant T-Cell Receptor-Like (TCRL) antibodies with the unique ability to bind with these intracellular peptide/MHC complexes with the specificity of cytotoxic T-cell killer cells.
AIT's technologies enable the generation of a rich pipeline of therapeutic TCRL antibodies for intracellularly-derived, disease-specific targets which normally are not accessible to conventional antibodies. TCRL antibodies also have diagnostic applications in vaccine design, validation and monitoring, as well as analysis of antigen presentation in disease.
Founded in 2006, AIT has a leading scientific team with extensive experience in molecular immunology. The company has a strong IP portfolio and extensive company know-how relating to target discovery, the TCRL technology, and specific TCRL antibodies and their targets.
AIT has completed lead optimization for its first application, malignant melanoma. The company is actively pursuing strategic partnerships with bio-pharmaceutical companies specializing in antibody development in order to discover new disease-specific targets, and to co-develop TCRL antibodies for the treatment of cancer and viral diseases.